Abstract: According to the present disclosure, the relation between the MeCP2 expression level and depression in D2R neurons of the ventral striatum was first found, and it was confirmed that MeCP2 in D2R neurons of the ventral striatum was significantly decreased due to depressive symptoms, and depressive symptoms were improved when MeCP2 expression in the neurons was up-regulated. Accordingly, the expression level of MeCP2 in D2R neurons of the ventral striatum is provided as a biomarker for diagnosing depression and the up-regulation of the MeCP2 expression is provided as a treatment strategy for depression, and thus, it is expected to be useful as a development platform for drugs for preventing or treating depression in the future.

Abstract: Disclosed is a composition for preventing or treating a degenerative brain disease. The composition includes, as an active ingredient, a MECP2 inhibitor for treating the degenerative brain disease, a polynucleotide encoding the MECP2 inhibitor or a recombinant virus containing the MECP2 inhibitor. The composition is useful for the treatment of a degenerative brain disease (particularly Alzheimer's syndrome) caused by beta-amyloid. In addition, the composition is effective in improving or ameliorating deterioration of cognitive functions and social deficits caused by Alzheimer's syndrome.

Abstract: Disclosed is a composition for diagnosing, preventing or treating drug addiction based on synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP). SYNCRIP or a gene encoding the protein can be used to diagnose drug addiction. In addition, a therapeutic agent for drug addiction can be discovered by measuring the expression of SYNCRIP. Furthermore, an agent expressing SYNCRIP or promoting the activity of SYNCRIP can be used to prevent or treat drug addiction.

Abstract: Disclosed is a composition for diagnosing, preventing or treating drug addiction based on synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP). SYNCRIP or a gene encoding the protein can be used to diagnose drug addiction. In addition, a therapeutic agent for drug addiction can be discovered by measuring the expression of SYNCRIP. Furthermore, an agent expressing SYNCRIP or promoting the activity of SYNCRIP can be used to prevent or treat drug addiction.

Abstract: The present invention relates to: A schizophrenia animal model wherein the model is a mouse in which an anoctamin 1 (ANO1) gene is knocked out in cholinergic neurons of a medial habenula; and a preparation method therefor and the like. The schizophrenia animal model according to the present invention targets the medial habenula which is brain tissue playing a major role in the pathogenesis of schizophrenia, and it has been confirmed that when the ANO1 gene is specifically knocked out in the cholinergic neurons of the medial habenula, positive, negative and cognitive symptoms of schizophrenia are observed, thereby confirming that schizophrenia has been induced. Therefore, the animal model of the present invention is expected to be effectively useful in schizophrenia pathogenesis research and therapeutic agent development and screening.

Abstract: Disclosed is a composition for preventing or treating a degenerative brain disease. The composition includes, as an active ingredient, a MECP2 inhibitor for treating the degenerative brain disease, a polynucleotide encoding the MECP2 inhibitor or a recombinant virus containing the MECP2 inhibitor. The composition is useful for the treatment of a degenerative brain disease (particularly Alzheimer's syndrome) caused by beta-amyloid. In addition, the composition is effective in improving or ameliorating deterioration of cognitive functions and social deficits caused by Alzheimer's syndrome.

Abstract: Disclosed is a composition for diagnosing, preventing or treating drug addiction based on synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP). SYNCRIP or a gene encoding the protein can be used to diagnose drug addiction. In addition, a therapeutic agent for drug addiction can be discovered by measuring the expression of SYNCRIP. Furthermore, an agent expressing SYNCRIP or promoting the activity of SYNCRIP can be used to prevent or treat drug addiction.

Abstract: Disclosed is a pharmaceutical composition for preventing or treating nicotine addiction or withdrawal symptoms. The pharmaceutical composition includes miR-137 as an active ingredient. Overexpression of miR-137 in an animal model having nicotine addiction or withdrawal symptoms results in relief, prevention or amelioration of the symptoms. Therefore, the use of miR-137 contributes to the prevention or treatment of nicotine addiction or withdrawal symptoms and is expected to be useful for developing relevant therapeutic agents.

Abstract: Disclosed is a pharmaceutical composition for preventing or treating nicotine addiction or withdrawal symptoms. The pharmaceutical composition includes miR-137 as an active ingredient. Overexpression of miR-137 in an animal model having nicotine addiction or withdrawal symptoms results in relief, prevention or amelioration of the symptoms. Therefore, the use of miR-137 contributes to the prevention or treatment of nicotine addiction or withdrawal symptoms and is expected to be useful for developing relevant therapeutic agents.

Abstract: The present invention relates to: A schizophrenia animal model wherein the model is a mouse in which an anoctamin 1 (ANO1) gene is knocked out in cholinergic neurons of a medial habenula; and a preparation method therefor and the like. The schizophrenia animal model according to the present invention targets the medial habenula which is brain tissue playing a major role in the pathogenesis of schizophrenia, and it has been confirmed that when the ANO1 gene is specifically knocked out in the cholinergic neurons of the medial habenula, positive, negative and cognitive symptoms of schizophrenia are observed, thereby confirming that schizophrenia has been induced. Therefore, the animal model of the present invention is expected to be effectively useful in schizophrenia pathogenesis research and therapeutic agent development and screening.

Abstract: The present disclosure relates to a biomarker for diagnosis of drug addiction and a kit for diagnosis of drug addiction. The biomarker for diagnosis of drug addiction and the kit for diagnosis of drug addiction according to the present disclosure can determine drug addiction by using a molecular biological method. Especially, the present disclosure has investigated molecular biologically how microRNA functions in the human brain due to drug addiction and how the microRNA is transferred to blood or serum by using an exosome as a means of transport. Therefore, the problem that, even though the change in the expression pattern of the microRNA in the brain is validated, it is difficult to apply the change in the expression pattern in the brain for clinical purposes directly and simply, was solved.